Zobrazeno 1 - 4
of 4
pro vyhledávání: '"In-Cheol Kang PhD"'
Autor:
Eunbin Kwag PhD, Soo-Dam Kim MD, PhD, Seong-Hoon Shin MD, PhD, Chulho Oak MD, PhD, So-Jung Park KMD, PhD, Jun-Yong Choi KMD, PhD, Seong Hoon Yoon MD, PhD, In-Cheol Kang PhD, Mi-Kyung Jeong KMD, PhD, Hyun Woo Lee MD, PhD, Sun-Hwi Bang KMD, PhD, Ji Woong Son MD, PhD, Sanghun Lee PhD, Seung Joon Kim MD, PhD, Hwa-Seung Yoo KMD, PhD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Background: Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has
Externí odkaz:
https://doaj.org/article/16dc59132dba49268b5fe5b711723fa5
Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer
Autor:
Si Yeon Song KMD, PhD, Ji Hye Park KMD, PhD, So-Jung Park KMD, PhD, In-Cheol Kang PhD, Hwa-Seung Yoo KMD, PhD
Publikováno v:
Integrative Cancer Therapies, Vol 21 (2022)
In epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), acquired resistance to EGFR tyrosine kinase inhibitors (TKI) leads to disease progression. Strategies to overcome the resistance are required in treatment for advan
Externí odkaz:
https://doaj.org/article/a449381b93914a5db32d074ba0b962e6
Autor:
Hwa Jeong Kang MS, Jeehye Kim MS, Seong Hyeok Cho MS, So-Jung Park OMD, Hwa-Seung Yoo OMD, In-Cheol Kang PhD
Publikováno v:
Integrative Cancer Therapies, Vol 18 (2019)
Epidermal growth factor receptor mutation-positive non–small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H
Externí odkaz:
https://doaj.org/article/0be7cf3f923a4137842618944131bc06
Autor:
Jin Ju Park MS, Ji Eun Kim PhD, Yoon Jeon PhD, Mi Rim Lee MS, Jun Young Choi MS, Bo Ram Song MS, Ji Won Park MS, Mi Ju Kang MS, Hyeon Jun Choi MS, Su Ji Bae MS, Ho Lee PhD, Byeong Cheol Kang PhD, Dae Youn Hwang PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 19 (2020)
Several techniques have been employed for deletion of the NKX3.1 gene, resulting in developmental defects of the prostate, including alterations in ductal branching morphogenesis and prostatic secretions as well as epithelial hyperplasia and dysplasi
Externí odkaz:
https://doaj.org/article/58044672342345d6a21deec1c7823c7f